Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01225887 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

NETWORK

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Mucinous Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Squamous Cell Carcinoma
Endometrial Transitional Cell Carcinoma
Endometrial Undifferentiated Carcinoma
Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm
Recurrent Uterine Corpus Carcinoma

Interventions

DRUG: Nintedanib

Sponsor

Gynecologic Oncology Group

Collaborators

[object Object]